-
ALC-0315: Practical LNP Formulation Guide
2026-09-15
This guide explains how to handle ALC-0315, an ionizable amino lipid used in lipid nanoparticle formulations for nucleic acid drug delivery and mRNA research. It focuses on solvent selection, storage, mixing, and quality control, while clarifying that product specifications do not by themselves establish a validated formulation, clinical performance, or suitability for direct aqueous use.
-
Tβ4 Promotes Angiogenesis in Critical Limb Ischemia
2026-09-15
Lv et al. show that thymosin-β4 enhances endothelial viability, migration, and angiogenic behavior in critical limb ischemia models through coordinated Notch and NF-κB pathway activity. By combining Tβ4 overexpression with DAPT and BMS pathway inhibition, the study provides pharmacological evidence for a mechanistic link that can inform vascular regeneration research while highlighting important translational limitations.
-
Alfuzosin HCl in Benign Prostatic Hyperplasia
2026-09-14
The reference review positions alfuzosin hydrochloride as a functionally uroselective α1 adrenoceptor antagonist that improves urinary symptoms and flow while limiting cardiovascular tolerability concerns. Its main translational contribution is the integration of prostate physiology, α1-adrenergic receptor signaling, pharmacokinetics, immediate-release versus extended-release formulations, and patient-centered outcomes.
-
Tranexamic Acid: Designing Better Fibrinolysis Studies
2026-09-14
A mechanism-to-translation guide for using Tranexamic Acid in plasmin assays, clot-stability models, and advanced wound-material research, with practical controls for separating molecular activity from formulation performance.
-
Moxidectin: Mechanism, Evidence, and Research Limits
2026-09-13
Moxidectin is a macrocyclic lactone anthelmintic used for parasitic worm control and supported by preclinical evidence as a polyene potentiator against Candida albicans. The 2024 study links this antifungal synergy to increased fungal ergosterol biosynthesis, but the finding does not establish moxidectin as an approved treatment for candidiasis.
-
In Vitro Drug Response Metrics in Cancer Research
2026-09-12
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability to separate proliferative arrest from actual cell killing in cancer drug assays. This framework improves interpretation of drug responses and supports more rigorous assay design, especially when compounds produce delayed or unequal effects on growth and death.
-
Bufalin and STK33: A Translational Cancer Playbook
2026-09-12
Bufalin is more than a natural-product apoptosis tool: emerging evidence positions this cardiotonic steroid as a target-engaging degrader with potential value in triple-negative breast cancer research. This article connects STK33 biology, molecular glue concepts, experimental validation, and translational decision-making.
-
Scutellaria Flavone 2′-Glucosides: 1995 Study
2026-09-11
The 1995 reference study established the structures of two previously unreported flavone 2′-O-glucosides from Scutellaria baicalensis roots and catalogued seven additional phenolics, including baicalin methyl ester. Its value is primarily chemical and taxonomic: chromatographic isolation combined with UV, NMR, NOESY, and high-resolution mass spectrometry provided a framework for identifying structurally related Scutellaria constituents before modern bioassay workflows.
-
Gasdermin C Drives PDAC Stemness and Immune Evasion
2026-09-11
This 2024 Advanced Science study identifies Gasdermin C (GSDMC) as a driver of pancreatic ductal adenocarcinoma stemness, metastasis, and immune evasion through a pyroptosis-independent nuclear mechanism. Its combination of single-cell discovery, mechanistic cleavage studies, murine perturbation models, and treatment-response analysis provides a framework for targeting aggressive PDAC cell states and improving responses to KRASG12D inhibition or PD-1 blockade.
-
Naloxone Hydrochloride in Withdrawal Assays
2026-09-10
Naloxone hydrochloride is more than an opioid receptor antagonist for overdose models. This assay-focused guide explains how it can distinguish endogenous opioid signaling from behavioral, stem-cell, and immune effects in translational research.
-
Azithromycin: An Evidence-First Assay Framework
2026-09-10
Azithromycin is a macrolide antibiotic whose value in research depends on more than a single MIC. This evidence-first guide connects ribosomal mechanism, formulation behavior, resistance testing, historical macrolide data, and trypanosomosis models to improve assay design and interpretation.
-
Ferroelectric Artificial Photoreceptor for Visual Adaptation
2026-09-09
Zhang and colleagues developed a ferroelectric-liquid metal hybrid film that converts visible and near-infrared light into electrical signals while reproducing key scotopic and photopic adaptation behaviors. Rodent experiments showed restored visible-light sensitivity, infrared perception, and stable in vivo integration, establishing a materials platform for broad-spectrum retinal prostheses.
-
FOXM1–ERα Biomarkers in Female Lung Adenocarcinoma
2026-09-09
This study integrates transcriptomic, survival, immune, and cell-based analyses to examine FOXM1 in female lung adenocarcinoma and proposes a DGCR5–hsa-miR-204-5p–FOXM1–ERα network. Its main practical value is the combination of computational biomarker discovery with FOXM1 knockdown experiments, while its mechanistic network and immunotherapy implications remain hypotheses requiring further validation.
-
Lovastatin and the Logic of Cell-State Exit
2026-09-08
Lovastatin is more than an HMG-CoA reductase inhibitor for routine viability testing. This article connects its metabolic effects with a plant meristem study to develop a more rigorous framework for interpreting proliferation, apoptosis, and macrophage efferocytosis assays.
-
CARDIO Reveals HSPB7 Rescue in Titin Cardiomyopathy
2026-09-08
Chopra and colleagues developed CARDIO, a high-content morphological profiling assay for human stem cell-derived cardiomyocytes, and used it to identify HSPB7 as a modifier of titin-associated cardiomyopathy. CRISPR knockout screening followed by engineered heart tissue validation showed that HSPB7 loss produced a hypertrophic phenotype while restoring contractile function in a titin disease model.